Who are CKD-825's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HM11260C, Physician's Choice of Endocrine Therapy, Rezvilutamide Tablets, Placebo,Fulvestrant,Goserelin acetate, GB491+ Fulvestrant, CKD-352.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ckd-825.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CKD-825 — Competitive Intelligence Brief

CKD-825 (CKD-825) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Estrogen Receptor Degrader (SERD). Area: Oncology.

phase 3 Selective Estrogen Receptor Degrader (SERD) Estrogen Receptor (ER) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CKD-825 (CKD-825) — Chong Kun Dang Pharmaceutical. CKD-825 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CKD-825 TARGET	CKD-825	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
HM11260C	HM11260C	Hanmi Pharmaceutical Company Limited	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Physician's Choice of Endocrine Therapy	Physician's Choice of Endocrine Therapy	Hoffmann-La Roche	phase 3	Selective estrogen receptor degrader (SERD)	Estrogen receptor
Rezvilutamide Tablets	Rezvilutamide Tablets	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Placebo,Fulvestrant,Goserelin acetate	Placebo,Fulvestrant,Goserelin acetate	Ahon Pharmaceutical Co., Ltd.	phase 3	Selective estrogen receptor degrader (SERD) + GnRH agonist combination	Estrogen receptor (ER) + GnRH receptor
GB491+ Fulvestrant	GB491+ Fulvestrant	Genor Biopharma Co., Ltd.	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-352	CKD-352	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Estrogen Receptor Degrader (SERD) class)

Chong Kun Dang Pharmaceutical · 7 drugs in this class
Hanmi Pharmaceutical Company Limited · 2 drugs in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Genor Biopharma Co., Ltd. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
AstraZeneca · 1 drug in this class
Nanjing Chia-tai Tianqing Pharmaceutical · 1 drug in this class
BeOne Medicines · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CKD-825 — Competitive Intelligence Brief. https://druglandscape.com/ci/ckd-825. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab